Benjamin L Maughan
Overview
Explore the profile of Benjamin L Maughan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
93
Citations
1560
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wiley H, Srinivasan R, Maranchie J, Chhablani J, Bondergaard Iversen A, Kruse A, et al.
Ophthalmology
. 2025 Feb;
132(3):374.
PMID: 39986707
No abstract available.
2.
Gebrael G, Sayegh N, Hage Chehade C, Jo Y, Narang A, Chigarira B, et al.
Prostate Cancer Prostatic Dis
. 2025 Jan;
PMID: 39885371
Introduction: Androgen deprivation therapy intensification (ADTi) with androgen receptor pathway inhibitors (ARPI), docetaxel or both has been shown to improve survival outcomes in patients with metastatic hormone-sensitive prostate cancer (mHSPC)....
3.
Sayegh N, Jo Y, Gebrael G, Tripathi N, Chigarira B, Srivastava A, et al.
Clin Genitourin Cancer
. 2024 Dec;
23(1):102287.
PMID: 39721833
Background: Enfortumab vedotin (EV) is a nectin-4-directed antibody and microtubule inhibitor conjugate indicated for patients with metastatic urothelial carcinoma (mUC) who have received prior platinum-based chemotherapy and PD-1/L1 inhibitors or...
4.
Maughan B, Liu Y, Mundle S, Wang X, Nematian-Samani M, Karsh L
Prostate Cancer Prostatic Dis
. 2024 Dec;
PMID: 39702472
Background: Androgen receptor pathway inhibitors (apalutamide [APA], enzalutamide [ENZ], abiraterone acetate plus prednisone [AAP]) combined with androgen-deprivation therapy (ADT) are effective life-prolonging treatment options for metastatic hormone-sensitive prostate cancer (mHSPC)....
5.
Gamvroulas E, Bailey E, Harrington E, Jones E, Martin R, Maughan B
Clin Genitourin Cancer
. 2024 Dec;
23(1):102279.
PMID: 39693710
Background: The National Comprehensive Cancer Network Bladder Cancer Guidelines recommend carboplatin and gemcitabine first-line treatment in patients with cisplatin-ineligible, metastatic urothelial cancer (mUC) -- a Category 1 recommendation. For these...
6.
Campbell P, Gebrael G, Narang A, Hage Chehade C, Mathew Thomas V, Galarza Fortuna G, et al.
Ther Adv Urol
. 2024 Nov;
16:17562872241293779.
PMID: 39524157
Background And Objectives: Intermittent androgen deprivation therapy (iADT) may result in measurable improvements in quality of life over continuous ADT in patients with advanced prostate cancer (aPC). Here, we studied...
7.
Iliopoulos O, Iversen A, Narayan V, Maughan B, Beckermann K, Oudard S, et al.
Lancet Oncol
. 2024 Sep;
25(10):1325-1336.
PMID: 39284337
Background: The first-in-class hypoxia-inducible factor-2α inhibitor, belzutifan, showed clinically meaningful antitumour activity in von Hippel-Lindau (VHL) disease-associated neoplasms in the ongoing, single-arm, phase 2 LITESPARK-004 study. We aimed to investigate...
8.
Narang A, Gebrael G, Jo Y, Mathew Thomas V, Li H, Galarza Fortuna G, et al.
Kidney Cancer
. 2024 Sep;
8(1):135-142.
PMID: 39263256
Background: Cabozantinib, a tyrosine kinase inhibitor (TKI), is a prevalent second-line (2 L) therapy and was approved for use after progression on TKIs. However, the 1 L treatment setting has...
9.
Galarza Fortuna G, Chigarira B, Mathew Thomas V, Sahu K, Kumar S, Tripathi N, et al.
J Kidney Cancer VHL
. 2024 Aug;
11(3):13-22.
PMID: 39100549
Thromboembolic events (TE) are a common complication in patients with metastatic renal cell carcinoma (mRCC) and are associated with poorer clinical outcomes. However, the incidence of TE and clinical and...
10.
Hage Chehade C, Jo Y, Gebrael G, Tripathi N, Sayegh N, Chigarira B, et al.
JAMA Netw Open
. 2024 Jul;
7(7):e2423186.
PMID: 39023888
Importance: Targeted therapies based on underlying tumor genomic susceptible alterations have been approved for patients with metastatic prostate cancer (mPC) and advanced urothelial carcinoma (aUC). Objective: To assess trends and...